PECULIARITIES OF THE III TYPE INTERFERON GENES’ POLYMORPHISM IN HCV PATIENTS ON THE CROSS-BORDER REGIONS OF RUSSIA AND MONGOLIA

Aims: determine the structure of IFNL3/IFNL4 interferon genes’ polymorphism in healthy people and in HCV patients and the frequency of spontaneous viral clearance in ethnic groups of Caucasians and Mongolians, living in the Asian part of Russia (Irkutsk Region) and in Mongolia.

Materials and methods: population genetic studies were conducted at 669 patients with hepatitis C, including 567 representatives Caucasian and 102 Mongoloid races. The control group consisted of 1520 healthy individuals, blood donors (800 Caucasians and 720 Mongoloids).

Results: it was found that in Caucasians patients with chronic hepatitis C were significantly less common CC genotype rs12979860, TT genotype rs8099917 and TT/TT genotype rs368234815, than in the general population. However, in patients with chronic hepatitis C, the representatives of the Mongoloid race, compared with healthy individuals, significant differences were found only in relation to the TT genotype rs8099917 IFNL3 gene. Spontaneous clearance of the virus was significantly more common in the Mongoloid race than in Caucasians.

Conclusions: the spontaneous viral clearance after clinical evidence or latent suffering hepatitis C was significantly more common in the Mongoloid race than in Caucasians that genetically determined high rate of prevalence in the population of the Mongols CC genotype rs12979860, TT genotype rs8099917 and TT/TT genotype rs368234815 polymorphisms of interferon type III genes.

1. Global hepatitis report 2017. Geneva: World Health Organization; 2017.

2. Yu M.L., Chuang W.L. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009; 24(3): 336-345. doi: 10.1111/j.1440-1746.2009.05789.x.

3. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O’Huigin C., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801. doi: 10.1038/nature08463.

4. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401. doi: 10.1038/nature08309.

5. Tanaka Y., Nishida N., Suqiyama M., Kurosaki M., Matsuura K., Sakomoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41(10): 1105–1109. doi: 10.1038/ng.449.

6. De Re V., Gragnani L., Fognani E., Piluso A., Izzo F., Mangia A., et al. Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed. Res. Int. 2014; 2014: 710642. doi: 10.1155/2014/710642.

7. Hayes C.N., Kobayashi M., Akuta N., Suzuki F., Kumada H., Abe H., et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut. – 2011; 60(2): 261-267. doi: 10.1136/gut.2010.223495

8. Xu H., Guo L.L., He L.L., Chen Y., Liu K., Lei B.J., Lei X.Z. Association of interleukin 28B polymorphisms with response to pegylated interferon plus ribavirin therapy for chronic hepatitis C. Sichuan Da Xue Xue Bao Yi Xue Ban. 2012; 43(6): 885-859.

9. Luo Y., Jin C., Ling Z., Mou X., Zhang Q., Xiang C. Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Gene. 2013; 513(2): 292-296. doi: 10.1016/j. gene.2012.10.030.

10. Prokunina-Olsson L., Muchmore B., Tang W., Pfeiffer R.M., Park H., Dickensheets H., et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013; 45(2): 164-171. doi: 10.1038/ng.2521.

11. Muchmore B., Tang W., Porter-Gill P., Kohaar I., Liu L., Brand N., et al. Identification and characterization of interferonλ4 (IFN- λ4), a novel class-2 cytokine which impairs clearance of hepatitis C virus (Abstract 182). Cytokine. 2013; 63(3): 286.

12. O’Brien T.R., Prokunina-Olsson L., Donnelly R.P. IFN-λ4: the paradoxical new member of the interferon lambda family. J. Interferon. Cytokine. Res. 2014; 34(11): 829-838. doi: 10.1089/jir.2013.0136.

13. Kruchkin Yu.N. Sovremennaya Mongoliya. Entsiklopedicheskii spravochnik. Ulan-Bator. 2011. 1154 p. (In Russ).

14. Statisticheskii byulleten’. Itogi vserossiiskoi perepisi naseleniya 2010 goda po Irkutskoi oblasti. Irkutsk: Irkutskstat. 2012. 52 p. (In Russ).

15. Ginzburg V. V. Elementy antropologii dlya medikov. Leningrad: Medgiz. 1963. 261 p. (In Russ).

16. Malov I.V., Malov S.I., Savilov E.D., Gantulga D., Stepanenko L.A., Ogarkov O.B. et al. A population-based polymorphism of the type IFNL3 and IFNL4 interferon genes associated with spontaneous HCV clearance in representatives of the Caucasoid and Mongoloid races. Byulleten’ eksperimental’noi biologii i meditsiny. 2016; 161(3): 382-385. (In Russ).

17. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol’nykh gepatitami B i C: Klinicheskie rekomendatsii. / Ed by Ivashkin V.T., Yushchuk N.D. – M.: Izdatel’stvo "GEOTARMedia". 2015. 144 p. (In Russ).

18. European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015. J. Hepatol. 2015; 63(1): 199-236. doi: 10.1016/j.jhep.2015.03.025.

19. Savilov E.D., Astaf’ev V.A., Zhdanova S.N., Zarudnev E.A. Epidemiologicheskii analiz: Metody statisticheskoi obrabotki materiala. Novosibirsk: Nauka-Tsentr. 2011. 156 p. (In Russ).

20. Pevnitsky L.A. Statistical assessment of associations between HLA antigens and diseases. Vestnik AMN SSSR. 1998; 7: 48-51. (In Russ).

21. Kozina A.N., Abramov D.D., Klimova E.A., Pypkina E.V., Dudina K.R., Yuschuk N.D., et al. Opportunities personalized approach to the treatment of hepatitis C on the basis of the developed genetic tests determine the version of the gene polymorphism of IL-28B. Lechashchiy vrach. 2011; 10; 39-43. (In Russ).

22. Kobayashi M., Suzuki F., Akuta N., Sezaki H., Suzuki Y., Hosaka T., et al. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J. Gastroenterol. 2012; 47(5): 596-605. doi: 10.1007/s00535-012-0531-1.

23. Xie J.Q., Zhang X.H., Li X.H., Xie D.Y., Xu Q.H. Genetic variation of IL-28B is associated with treatment response of patients with chronic hepatitis C // Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012; 26(4): 298-300.

24. Huang C.F., Yeh M.L., Hsieh M.H., Hsieh M.Y., Lin Z.Y., Chen S.C., et al. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin. J. Gastroenterol. Hepatol. 2013; 28(9): 1515-1520. doi: 10.1111/jgh.12211.

25. Smith K.R., Suppiah V., O’Connor K., Berg T., Weltman M., Abate M.L., et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in a treatment of hepatitis C using massively parallel sequencing in a crosssection European cohort. Genome Med. 2011; 3(8): 57. doi: 10.1186/gm273.

26. Hashimoto Y., Ochi H., Abe H., Hayashida Y., Tsuge M., Mitsui F., et al. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J. Med. Virol. 2011; 83(6): 981-988. doi: 10.1002/jmv.22028.

27. Hanuka N., Sikuler E., Toybir D., Mostoslavsky M., Hausman M., Orgel M., et al. Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies. J. Viral. Hepat. 2002; 9(2): 141-145.

28. Baranov A.V., Maleev V.V. Association between HCV RNA level and HCV antibodies during chronic hepatitis C. Zh. Mikrobiol. Epidemiol. Immunobiol. 2009; 5: 19-22 (In Russ).

29. Lai M.E., Origa R., Danjou F., Leoni G.B., Vacquer S., Anni F., et al. Natural history of hepatitis C in thalassemia major: a long-term prospective study. Eur. J. Haematol. 2013; 90(6): 501-507. doi: 10.1111/ejh.12086.

30. Maor Y., Morali G., Bashari D., Penaranda G., Schapiro J.M., Martinowitz U., Halfon P. Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel. Haemophilia. 2013; 19(1): 150-156. doi: 10.1111/j.13652516.2012.02932.x.